✦ LIBER ✦

Two years of treatment with liraglutide, a human GLP-1 analogue, offers sustained and greater reduction with HbA1c, FPG, PPG and weight compared with glimepiride, with lower glycaemic risk, in patients with type 2 diabetes: LEAD-3 extension study

✍ Scribed by Garber, A.; Henry, R.; Ratner, R.E.; Hale, P.; Chang, C.T.; Bode, B.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Liraglutide, a once-daily human glucagon

✍ A. Garber; R. R. Henry; R. Ratner; P. Hale; C. T. Chang; B. Bode 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 971 KB

Patient-reported outcomes following trea

✍ B. W. Bode; M. A. Testa; M. Magwire; P. M. Hale; M. Hammer; L. Blonde; A. Garber 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 556 KB

One year of liraglutide treatment offers

✍ R. Pratley; M. Nauck; T. Bailey; E. Montanya; R. Cuddihy; S. Filetti; A. Garber; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 510 KB

Weight loss with liraglutide, a once-dai

✍ J. Jendle; M. A. Nauck; D. R. Matthews; A. Frid; K. Hermansen; M. Düring; M. Zdr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB